Article
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma.
Cellular oncology (Dordrecht, Netherlands) - 1 Apr 2023
Coupe Nicholas, Guo Lina, Bridges Esther, Campo Leticia, Espinosa Olivia, Colling Richard, Marshall Andrea, Nandakumar Ashwin, van Stiphout Ruud, Buffa Francesca M, Corrie Pippa G, Middleton Mark R, Macaulay Valentine M
Abstract excerpt
PURPOSE: Despite recent advances, approximately 50% of patient with metastatic melanoma eventually succumb to the disease. Patients with melanomas harboring a BRAF mutation (BRAFMut) have a worse prognosis than those with wildtype (BRAFWT) tumors. Unexpectedly, interim AVAST-M Phase III trial data reported benefit from adjuvant anti-VEGF bevacizumab only in the BRAFMut group. We sought to find mechanisms...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.